<DOC>
	<DOCNO>NCT02302807</DOCNO>
	<brief_summary>This Phase III , global , multicenter , open-label , two-arm , randomize , control study design evaluate efficacy safety atezolizumab compare chemotherapy participant locally advance metastatic urothelial bladder cancer ( UBC ) progress follow platinum-containing regimen . The anticipated time study treatment base continued clinical benefit , i.e. , disease progression unacceptable toxicity . The target sample size 932 participant .</brief_summary>
	<brief_title>A Study Atezolizumab Compared With Chemotherapy Participants With Locally Advanced Metastatic Urothelial Bladder Cancer IMvigor211</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically cytologically document locally advanced metastatic UBC ( include renal pelvis , ureter , urinary bladder , urethra ) Representative tumor specimen specify protocol Disease progression follow treatment least one platinumcontaining regimen inoperable , locally advanced metastatic UBC disease recurrence Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Life expectancy great equal ( &gt; /= ) 12 week Measurable disease , define RECIST v1.1 Adequate hematologic end organ function For female participant childbearing potential male participant partner childbearing potential , agreement ( participant and/or partner ) use highly effective form ( ) contraception define protocol continue use 90 day last dose atezolizumab Any approve anticancer therapy within 3 week prior initiation study treatment Treatment investigational agent participation another clinical trial therapeutic intent within 28 day prior enrollment Active untreated central nervous system ( CNS ) metastasis determine compute tomography ( CT ) magnetic resonance imaging ( MRI ) evaluation screen prior radiographic assessment Leptomeningeal disease Malignancies UBC within 5 year prior Cycle 1 , Day 1 , exception negligible risk metastasis death treat expect curative outcome , localized prostate cancer treat curative intent absence prostatespecific antigen ( PSA ) relapse incidental prostate cancer Pregnant lactate woman Significant cardiovascular disease Severe infection within 4 week prior randomization Major surgical procedure diagnosis within 4 week prior randomization History severe allergic , anaphylactic , hypersensitivity reaction chimeric humanize antibody fusion protein ; know hypersensitivity allergy biopharmaceuticals produce Chinese hamster ovary cell component atezolizumab formulation History autoimmune disease Prior allogeneic stem cell solid organ transplant History idiopathic pulmonary fibrosis , organize pneumonia , druginduced pneumonitis , idiopathic pneumonitis , evidence active pneumonitis screen chest CT scan Positive test human immunodeficiency virus ( HIV ) and/or active hepatitis B hepatitis C tuberculosis Administration live , attenuate vaccine within 4 week prior randomization Prior treatment cluster differentiation 137 ( CD137 ) agonists immune checkpoint blockade therapy , include anticytotoxic Tlymphocyteassociated protein 4 ( antiCTLA4 ) , antiprogrammed death1 ( antiPD1 ) antiprogrammed deathligand 1 ( antiPDL1 ) therapeutic antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>